Avalo Therapeutics, Inc. (AVTX)
13.65
+0.22
(+1.64%)
USD |
NASDAQ |
Oct 09, 16:00
13.65
0.00 (0.00%)
After-Hours: 20:00
Avalo Therapeutics Net Income (Quarterly) : -36.36M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -36.36M |
| March 31, 2026 | -19.63M |
| December 31, 2025 | -13.72M |
| September 30, 2025 | -30.62M |
| June 30, 2025 | -20.76M |
| March 31, 2025 | -13.15M |
| December 31, 2024 | -35.34M |
| September 30, 2024 | 23.04M |
| June 30, 2024 | 98.46M |
| March 31, 2024 | -121.29M |
| December 31, 2023 | -8.168M |
| September 30, 2023 | -5.228M |
| June 30, 2023 | -8.193M |
| March 31, 2023 | -9.955M |
| December 31, 2022 | -9.812M |
| September 30, 2022 | 3.192M |
| June 30, 2022 | -12.99M |
| March 31, 2022 | -22.05M |
| December 31, 2021 | -19.13M |
| September 30, 2021 | -17.47M |
| June 30, 2021 | -17.17M |
| March 31, 2021 | -30.57M |
| December 31, 2020 | -16.14M |
| September 30, 2020 | -13.26M |
| Date | Value |
|---|---|
| June 30, 2020 | -12.83M |
| March 31, 2020 | -22.15M |
| September 30, 2019 | -2.930M |
| June 30, 2019 | -2.544M |
| March 31, 2019 | -5.162M |
| December 31, 2018 | -7.217M |
| September 30, 2018 | -24.60M |
| June 30, 2018 | -6.008M |
| March 31, 2018 | -3.883M |
| December 31, 2017 | -7.189M |
| September 30, 2017 | 18.72M |
| June 30, 2017 | -1.798M |
| March 31, 2017 | -1.961M |
| December 31, 2016 | -1.639M |
| September 30, 2016 | -6.169M |
| June 30, 2016 | -3.524M |
| March 31, 2016 | -5.14M |
| December 31, 2015 | -3.648M |
| September 30, 2015 | -0.6911M |
| June 30, 2015 | -2.913M |
| March 31, 2015 | -3.238M |
| June 30, 2014 | -4.064M |
| March 31, 2014 | -3.628M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AbbVie, Inc. | 3.604B |
| Rezolute, Inc. | -20.49M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 36.36M |
| EPS Diluted (Quarterly) | -0.8339 |
| Enterprise Value | 324.01M |
| Earnings Yield | -34.72% |
| Normalized Earnings Yield | -30.79 |